

Abacus Medicine Pharma Services and Luye Pharma sign distribution agreement for Named Patient Program (NPP) of Lurbinectedin in Hong Kong


9th January, 2023

Abacus Medicine Pharma Services (AMPS) and Luye Pharma Group are proud to announce the signing of an exclusive distribution contract to make Lurbinectedin available to small cell lung cancer patients in Hong Kong via the Named Patient Program (NPP).

Lurbinectedin is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

This indication is approved by the U.S. Food and Drug Administration (FDA) under accelerated approval based on overall response rate and duration of response in an open-label, monotherapy clinical trial.

The agreement provides AMPS with exclusive distribution rights for Lurbinectedin to the oncology community in Hong Kong.



Andy Siow, APAC Regional Director of Luye Pharma (International) and William Van, General Manager, Abacus Medicine Pharma Services Asia Limited signing distribution agreement for Named Patient Program of Lurbinectedin.

Signing Ceremony took place at Champion Tower, Central, Hong Kong.

William Van, General Manager, Abacus Medicine Pharma Services Asia Limited explains: “We have been developing an excellent relationship with Luye Pharma over the past two years and this NPP partnership is an exciting project to show both the developments taking place within the Chinese pharmaceutical industry and also the development of Abacus Medicine Pharma Services Asia Limited as a recognised pharma services company within the APAC region.”

Continuing, Andy Siow, APAC Regional Director of Luye Pharma (International) explains, “The development of Lurbinectedin is a key milestone in the history of SCLC and we are delighted to partner with Abacus Medicine Pharma Services to make Lurbinectedin accessible to the patients in Hong Kong via this NPP. This represents a significant development of the Luye Pharma oncology portfolio in the region.”

Abacus Medicine Pharma Services (AMPS) is part of the Abacus Medicine Group, a fast-growing supplier of original prescription medicines. 1,100 employees service thousands of customers in Europe and the rest of the world. With a customised ERP system, a bespoke global distribution centre and a leadership team with decades of experience, AMPS is evolving into the next-generation healthcare and pharma services company by combining the infrastructure and skills at Abacus Medicine with the experience and expertise within AMPS.

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of over 30 drug candidates in China and more than 10 drug candidates in other international markets. Along with a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S., Europe and Japan, Luye Pharma maintains high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems. The company has achieved multiple innovations in new chemical entities and antibodies and is also actively making strategic developments in the fields of cell therapies and gene therapies.

Luye Pharma is developing a global supply chain of 8 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. With more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., Europe and Japan, as well as in fast growing emerging markets.

Company contacts: -

Abacus Medicine Pharma Services Asia Limited
Sharon Leung, Administration and Logistics Coordinator
Email: sharon.leung@abacusmedicine.com
Phone: +852 9419 1132
www.abacusmedicinepharmaservices.com

Luye Pharma Group
Vivian Weng, Deputy Public Relations Director
Email: vivianweng@luye.com
Phone: +86 21 5389 4245
www.luye.cn/lvye_en/